| アブストラクト | Evidence suggests that older people aged >/=65 years and those aged 60-64 years with chronic medical conditions are at higher risk of developing severe complications due to influenza virus infection when compared with young, healthy adults. Although seasonal influenza is monitored through a nationwide passive surveillance in Japan, influenza related outcomes and medical resource consumption have not been fully documented. This retrospective database study aimed to describe the epidemiological and clinical characteristics of medically attended influenza cases aged >/=60 years and the associated medical resource consumption in Japan. We used clinically diagnosed influenza (CDI) based on the international classification of disease codes, and laboratory-confirmed influenza (LCI) based on influenza test results, to identify the patient population during a total of nine seasons (2010/2011 to 2018/2019). A total of 372,356 CDI and 31,122 LCI cases were identified from 77 medical institutions. The highest numbers of medically-attended influenza episodes were in patients aged 65-74 years and 75-84 years. On average, across seasons, 5.9% of all-cause hospitalizations were attributable to CDI and 0.4% were LCI. Influenza viruses type A and B co-circulated annually in varying degree of intensity and were associated with similar level of complications, including cardiovascular-related. Oxygen therapy increased with age; by contrast, mechanical ventilation, dialysis, blood transfusion, and intensive care unit admission were higher in the younger groups. In-hospital mortality for inpatients aged >/= 85 years with CDI and LCI were 18.6% and 15.5%, respectively. Considering the burden associated with medically-attended influenza in this population, influenza prevention, laboratory confirmation and clinical management should be emphasized by general practicians and specialists like cardiologists to protect this aging population. |
|---|
| 組織名 | Medical Evidence Generation, Medical Affairs, Sanofi, Tokyo, Japan.;Department of Health Economics and Outcomes Research, Graduate School of;Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.;Department of Cardiology, Tokyo Metropolitan Geriatric Hospital and Institute of;Gerontology, Tokyo, Japan.;Medical Evidence Generation, Medical Affairs, Sanofi, Lyon, France.;Li Ka Shing Faculty of Medicine, World Health Organization Collaborating Centre;for Infectious Disease Epidemiology and Control, School of Public Health, The;University of Hong Kong, Hong Kong Special Administrative Region, China.;Research and Analytics Department, Real World Data, Co., Ltd., Kyoto, Japan.;The Initiative for Clinical Epidemiological Research, Tokyo, Japan.;Department of Modelling, Epidemiology and Data Science, Sanofi Pasteur, Lyon,;France.;Foundation for Influenza Epidemiology, Fondation de France, Paris, France. |
|---|
